New hope for lymphoma patients: drug duo aims to shrink tumors

NCT ID NCT06390956

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, pirtobrutinib and rituximab, can shrink or eliminate tumors in people newly diagnosed with marginal zone lymphoma. About 23 adults will receive the combination and be checked for response after several cycles. The goal is to control the disease, not to cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Huntsman Cancer Institute at University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Washington University
RECRUITING

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.